Here's Why I'm Avoiding SpaceX Stock After the IPO

SpaceX is expected to pursue a record $2 trillion IPO, implying a 129x price-to-sales ratio versus the S&P 500's 3.5x average. The article argues the company is already mature, with 2025 revenue growth slowing to 18% from 51% in 2024 and 89% in 2023, while generative AI spending tied to xAI has reportedly contributed to a $5 billion loss in 2025. It warns that the IPO's scale, valuation, and AI pivot could limit upside and increase post-listing risk.

Analysis

This is less a clean equity IPO than a liquidity event wrapped around a strategic reset. The market is likely to treat the listing as a proxy for frontier-tech optionality, but the business mix is becoming harder to underwrite because capital is being diverted toward a cyclical, winner-take-most AI buildout that can obscure core operating performance for years. That matters because once a large, high-profile private asset hits public markets, investors typically anchor to the headline narrative and underestimate the dilution of focus and the rising cost of capital if the AI spend disappoints.

The second-order effect is that public-market pricing discipline could quickly collide with private-market expectations. If management uses IPO proceeds to subsidize long-duration infrastructure, the equity becomes a funding vehicle rather than a cash-compounding operating company, which usually compresses multiple support once growth decelerates further. The key setup is that enthusiasm may carry the stock for weeks or months post-listing, but the fundamental test arrives over 2-4 quarters when public investors demand a credible path from spend to monetization.

The beneficiaries are likely to be adjacent infrastructure suppliers and compute enablers, not the issuer itself, because the AI capex wave has better near-term visibility than the combined entity’s long-dated economics. The most vulnerable names are any public comparables trading on scarcity value or “AI-adjacent” narratives; a disappointingly priced mega-IPO tends to reset expectations across the category and can pressure private-marked peers. The contrarian view is that the market may be underestimating how much optionality a dominant capital base creates, but that only matters if management resists turning the company into a conglomerate of speculative projects.

For now, the setup looks more like a sell-the-dream event than a durable compounding story. The risk/reward improves materially only if the listing clears with a much smaller valuation, tighter ring-fencing of AI spend, or a governance structure that forces capital discipline. Absent that, the equity likely trades as a crowded momentum vehicle with limited upside and meaningful post-IPO disappointment risk.

Key Decisions for Investors

• Avoid chasing the IPO in the first 30-90 days; let the initial price discovery resolve before taking exposure, because post-listing multiple compression risk is highest when the market re-rates growth and capex quality.
• If a public listing occurs near the implied $2T area, consider a tactical short via listed options 3-6 months out, targeting a 20-30% downside move if AI spend remains loss-making and disclosure is weak.
• Use the event to buy beneficiaries of the AI capex cycle rather than the issuer: prefer NVDA on any post-IPO pullback for 6-12 months if listed-market enthusiasm shifts toward infrastructure demand rather than end-user monetization.
• For a relative-value expression, pair long NVDA / short high-multiple, narrative-driven AI names that lack clear cash-flow visibility; the IPO could force a broader de-rating of speculative AI adjacency over 1-2 quarters.
• Do not add INTC on this theme alone; if anything, monitor for a sympathy bid in legacy compute supply chains and fade it unless there is evidence the combined entity is driving incremental, contracted demand.